Cellular Biomedicine Group (CBMG) says it hopes to leverage R&D work done in China to expedite clinical trials in the US as it establishes facilities in Maryland. Last month, Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) announced plans to build a 22,000 square foot facility in Rockville, Maryland. The site will be the first outside China for the firm and is intended to initially support US clinical trials for its cell-based candidates targeting hematological indications. Speaking on its Q3 2019 conference…